Kenneth Galbraith, Zymeworks CEO
December 19, 2022 11:35 AM EST
R&D

Zymeworks shows pos­i­tive — yet ear­ly — piv­otal da­ta in bile duct can­cers, plans ac­cel­er­at­ed ap­proval run

Paul Schloesser

Associate Editor

Zymeworks is show­ing off some new topline da­ta on its HER2 bis­pe­cif­ic an­ti­body — af­ter show­cas­ing a pos­i­tive da­ta turnout at AS­CO ear­li­er in 2022. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times